Announcements
January 11, 2019 – Saol Therapeutics Announces that CDC Website has Been Updated to Reflect Wide Availability of VARIZIG® (Varicella Zoster Immune Globulin [Human])
August 16, 2018 – Spasticity-related pain reduction and quality of life improvements seen in patients with post-stroke severe spasticity
January 11,2018 – New level 1 evidence for post-stroke severe spasticity
September 1, 2017 – Saol Therapeutics acquires three hyperimmune products from Aptevo Therapeutics
June 30, 2017 – Saol Therapeutics signs co-promotion agreement with Ipsen Biopharmaceuticals for Dysport® (abobotulinumtoxinA)
January 15, 2016 – Saol Therapeutics acquires Lioresal® Intrathecal (baclofen injection)
For full prescribing information of Lioresal® Intrathecal (baclofen injection), including BOX WARNING, please click here.
For full prescribing information of Dysport®, including BOX WARNING, please click here.
DYSPORT is a registered trademark of Ipsen Biopharm Limited.